Jacques-Eric Gottenberg

List of Publications by Year
in descending order

108	14,536	44069 48	30087 103
papers	citations	h-index	g-index

110	110	110	11857
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 2017, 76, 960-977.	0.9	3,366
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 685-699.	0.9	1,860
3	EULAR SjÃ¶gren's syndrome disease activity index: development of a consensus systemic disease activity index for primary SjÃ¶gren's syndrome. Annals of the Rheumatic Diseases, 2010, 69, 1103-1109.	0.9	734
4	Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2770-2775.	7.1	542
5	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 909-920.	0.9	394
6	EULAR SjÃ¶gren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary SjÃ¶gren's syndrome. Annals of the Rheumatic Diseases, 2011, 70, 968-972.	0.9	383
7	Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. Arthritis and Rheumatism, 2010, 62, 2458-2466.	6.7	352
8	Treatment of Primary SjÃ¶gren Syndrome With Rituximab. Annals of Internal Medicine, 2014, 160, 233-242.	3.9	325
9	EULAR recommendations for the management of SjÃ¶grenâ€™s syndrome with topical and systemic therapies. Annals of the Rheumatic Diseases, 2020, 79, 3-18.	0.9	307
10	Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis and Rheumatism, 2010, 62, 2625-2632.	6.7	266
11	Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Annals of the Rheumatic Diseases, 2007, 66, 351-357.	0.9	261
12	Effects of Hydroxychloroquine on Symptomatic Improvement in Primary SjÃ¶gren Syndrome. JAMA - Journal of the American Medical Association, 2014, 312, 249.	7.4	241
13	EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide. RMD Open, 2015, 1, e000022-e000022.	3.8	229
14	Defining disease activity states and clinically meaningful improvement in primary SjÃ¶gren's syndrome with EULAR primary SjÃ¶gren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Annals of the Rheumatic Diseases, 2016, 75, 382-389.	0.9	225
15	Characterization of systemic disease in primary SjÃ¶gren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology, 2015, 54, 2230-2238.	1.9	220
16	Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy. JAMA - Journal of the American Medical Association, 2019, 322, 315.	7.4	210
17	Efficacy of rituximab in systemic manifestations of primary SjÃ¶gren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Annals of the Rheumatic Diseases, 2013, 72, 1026-1031.	0.9	193
18	Validation of EULAR primary SjÃ¶gren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Annals of the Rheumatic Diseases, 2015, 74, 859-866.	0.9	193

#	Article	IF	Citations
19	Nonâ€“TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug. JAMA - Journal of the American Medical Association, 2016, 316, 1172.	7.4	160
20	Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Annals of the Rheumatic Diseases, 2007, 66, 700-702.	0.9	159
21	Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology, 2011, 50, 222-229.	1.9	159
22	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Annals of the Rheumatic Diseases, 2021, 80, 36-48.	0.9	153
23	In primary SjÃ¶gren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis and Rheumatism, 2003, 48, 2240-2245.	6.7	150
24	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Annals of the Rheumatic Diseases, 2017, 76, 386-391.	0.9	150
25	Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary SjÃ¶grenâ€™s Syndrome. Data at Enrollment in the Prospective ASSESS Cohort. PLoS ONE, 2013, 8, e59868.	2.5	147
26	Viruses induce high expression of BAFF by salivary gland epithelial cells through TLRâ€•and typeâ€‘IFNâ€dependent and â€‘independent pathways. European Journal of Immunology, 2008, 38, 1058-1064.	2.9	141
27	Influence of geolocation and ethnicity on the phenotypic expression of primary SjÃ¶gren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data SjÃ¶gren Project Consortium. Annals of the Rheumatic Diseases, 2017, 76, 1042-1050.	0.9	132
28	Differentiation of follicular helper T cells by salivary gland epithelial cells in primary SjÃ¶gren's syndrome. Journal of Autoimmunity, 2014, 51, 57-66.	6.5	123
29	Early diagnosis of primary SjÃ¶grenâ€™s syndrome: EULAR-SS task force clinical recommendations. Expert Review of Clinical Immunology, 2016, 12, 137-156.	3.0	118
30	Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the â€˜Orencia and Rheumatoid Arthritisâ€™ registry. Annals of the Rheumatic Diseases, 2012, 71, 1815-1819.	0.9	117
31	B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Research and Therapy, 2013, 15, R168.	3.5	115
32	The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary SjÃ¶gren's syndrome. Arthritis and Rheumatism, 2009, 60, 1991-1997.	6.7	104
33	Brief Report: Association of Rheumatoid Factor and Antiâ€“Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Panâ€European Registry Analysis. Arthritis and Rheumatology, 2016, 68, 1346-1352.	5.6	102
34	Classification criteria for SjÃ¶gren's syndrome: we actually need to definitively resolve the long debate on the issue. Annals of the Rheumatic Diseases, 2013, 72, 476-478.	0.9	90
35	B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis. Journal of Autoimmunity, 2015, 56, 1-11.	6.5	88
36	Pathogenesis of SjÃ¶gren's syndrome and therapeutic consequences. Current Opinion in Rheumatology, 2010, 22, 471-477.	4.3	78

#	Article	IF	Citations
37	Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjogren's syndrome and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2007, 66, 790-797.	0.9	77
38	Outcome measures for primary SjÃ¶gren's syndrome: A comprehensive review. Journal of Autoimmunity, 2014, 51, 51-56.	6.5	77
39	Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ: British Medical Journal, 2019, 364, l67.	2.3	76
40	Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Annals of the Rheumatic Diseases, 2012, 71, 1243-1248.	0.9	74
41	Efficacy and safety of abatacept in active primary SjÃ¶grenâ€™s syndrome: results of a phase III, randomised, placebo-controlled trial. Annals of the Rheumatic Diseases, 2021, 80, 339-348.	0.9	63
42	Association of Antiâ€“‹i›Porphyromonas gingivalis‹/i› Antibody Titers With Nonsmoking Status in Early Rheumatoid Arthritis: Results From the Prospective French Cohort of Patients With Early Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 1729-1737.	5.6	61
43	Interleukin 6 receptor inhibition in primary SjÃ¶gren syndrome: a multicentre double-blind randomised placebo-controlled trial. Annals of the Rheumatic Diseases, 2021, 80, 329-338.	0.9	61
44	Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. Annals of the Rheumatic Diseases, 2016, 75, 1945-1950.	0.9	57
45	Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology, 2011, 50, 2283-2289.	1.9	56
46	Efficacy and safety of rituximab for systemic lupus erythematosusâ€associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. American Journal of Hematology, 2018, 93, 424-429.	4.1	56
47	Evaluation of Serum Interleukinâ€6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort. Arthritis Care and Research, 2015, 67, 905-912.	3.4	55
48	Epidemiological profile and northâ€“south gradient driving baseline systemic involvement of primary SjÃ¶grenâ€™s syndrome. Rheumatology, 2020, 59, 2350-2359.	1.9	54
49	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of SjÃ¶grenâ€™s syndrome. RMD Open, 2019, 5, e001064.	3.8	53
50	Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort. Scientific Reports, 2016, 6, 18421.	3.3	51
51	Hydroxychloroquine treatment downregulates systemic interferon activation in primary SjÃ¶grenâ€™s syndrome in the JOQUER randomized trial. Rheumatology, 2020, 59, 107-111.	1.9	50
52	Development of the SjÃ¶grenâ€™s Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology, 2015, 54, 1699-1708.	1.9	49
53	Efficacy of Epratuzumab, an Antiâ€‹scp›CD‹/scp›22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated SjÃ¶gren's Syndrome. Arthritis and Rheumatology, 2018, 70, 763-773.	5.6	49
54	Outcome measures for primary SjÃ¶grenâ€™s syndrome. Journal of Autoimmunity, 2012, 39, 97-102.	6.5	46

#	Article	IF	Citations
55	Role of Fmsâ€like Tyrosine Kinase 3 Ligand as a Potential Biologic Marker of Lymphoma in Primary SjÃ¶gren's Syndrome. Arthritis and Rheumatism, 2013, 65, 3218-3227.	6.7	46
56	Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection. Rheumatology, 2018, 57, 538-547.	1.9	43
57	Brief Report: Defective Early B Cell Tolerance Checkpoints in SjÃ¶gren's Syndrome Patients. Arthritis and Rheumatology, 2017, 69, 2203-2208.	5.6	40
58	Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab. Lancet Rheumatology, The, 2022, 4, e13-e16.	3.9	40
59	Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Annals of the Rheumatic Diseases, 2022, 81, 184-192.	0.9	40
60	No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary SjÃ¶gren's syndrome. Arthritis Research and Therapy, 2006, 8, R30.	3.5	38
61	How immunological profile drives clinical phenotype of primary SjÃ¶gren's syndrome at diagnosis: analysis of 10,500 patients (SjÃ¶gren Big Data Project). Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 102-112.	0.8	37
62	BAFF synthesis by rheumatoid synoviocytes is positively controlled by Î±5Î²1 integrin stimulation and is negatively regulated by tumor necrosis factor Î± and tollâ€like receptor ligands. Arthritis and Rheumatism, 2007, 56, 3202-3214.	6.7	35
63	Bâ€cellâ€activating factor expressions in salivary epithelial cells after dsRNA virus infection depends on RNAâ€activated protein kinase activation. European Journal of Immunology, 2009, 39, 1271-1279.	2.9	35
64	Role of the IL-12/IL-35 balance in patients with SjÃ¶gren syndrome. Journal of Allergy and Clinical Immunology, 2018, 142, 258-268.e5.	2.9	34
65	The classical NLRP3 inflammasome controls FADD unconventional secretion through microvesicle shedding. Cell Death and Disease, 2019, 10, 190.	6.3	33
66	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 650-657.	5.8	32
67	The pipeline of targeted therapies under clinical development for primary SjÃ¶gren's syndrome: A systematic review of trials. Autoimmunity Reviews, 2019, 18, 576-582.	5.8	31
68	Composite of Relevant Endpoints for SjÃ¶gren's Syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatology, The, 2021, 3, e553-e562.	3.9	31
69	Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry. Lancet Rheumatology, The, 2022, 4, e8-e11.	3.9	29
70	Development and preliminary validation of the SjÃ¶grenâ€™s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary SjÃ¶grenâ€™s syndrome. Annals of the Rheumatic Diseases, 2022, 81, 979-989.	0.9	27
71	A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary SjÃ¶grenâ€™s syndrome. Rheumatology, 2021, 60, 1364-1375.	1.9	26
72	Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: Table 1. Rheumatology, 2016, 56, kew271.	1.9	22

#	Article	IF	Citations
73	Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients. RMD Open, 2017, 3, e000555.	3.8	20
74	Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary SjÃ¶grenâ€™s Syndrome?. PLoS ONE, 2015, 10, e0133907.	2.5	19
75	Discrepancy of Serological and Molecular Patterns of Circulating Epstein-Barr Virus Reactivation in Primary SjÃ¶gren's Syndrome. Frontiers in Immunology, 2019, 10, 1153.	4.8	19
76	Sicca/SjÃ¶gren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 114-122.	0.8	19
77	B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2021-220549.	0.9	18
78	Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. Rheumatology, 2022, 61, 953-962.	1.9	15
79	Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?. Annals of the Rheumatic Diseases, 2019, 78, 860-862.	0.9	14
80	Revisiting the JOQUER trial: stratification of primary SjÃ¶grenâ€™s syndrome and the clinical and interferon response to hydroxychloroquine. Rheumatology International, 2021, 41, 1593-1600.	3.0	13
81	Influence of the age at diagnosis in the disease expression of primary SjÃ¶gren syndrome. Analysis of 12,753 patients from the SjÃ¶gren Big Data Consortium. Clinical and Experimental Rheumatology, 2021, 39, 166-174.	0.8	12
82	Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study. European Journal of Internal Medicine, 2021, 85, 41-49.	2.2	11
83	Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry. Rheumatology, 2017, 56, kew476.	1.9	10
84	Idiosyncratic Drug-Induced Severe Neutropenia and Agranulocytosis in Elderly Patients (â‰¥75Âyears): A Monocentric Cohort Study of 61 Cases. Drugs - Real World Outcomes, 2016, 3, 393-399.	1.6	9
85	Identification of cartilage oligomeric matrix protein as biomarker predicting abatacept response in rheumatoid arthritis patients with insufficient response to a first anti-TNFÎ± treatment. Joint Bone Spine, 2019, 86, 401-403.	1.6	8
86	Seasonal effect on fatigue, pain and dryness in primary SjÃ¶grenâ€™s syndrome. Arthritis Research and Therapy, 2020, 22, 39.	3.5	8
87	Response to: â€˜Correspondence on â€˜Interleukin 6 receptor inhibition in primary SjÃ¶gren syndrome: a multicentre double-blind randomised placebo-controlled trialâ€™â€™ by Wang et al. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2021-219882.	0.9	8
88	Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis. Arthritis Research and Therapy, 2018, 20, 122.	3.5	7
89	Classification criteria and treatment modalities in primary SjÃ¶grenâ€™s syndrome. Expert Review of Clinical Immunology, 2014, 10, 543-551.	3.0	6
90	History and Outcome of Febrile Neutropenia Outside the Oncology Setting: A Retrospective Study of 76 Cases Related to Non-Chemotherapy Drugs. Journal of Clinical Medicine, 2017, 6, 92.	2.4	6

#	Article	IF	Citations
91	When biologics should be used in systemic lupus erythematosus?. Presse Medicale, 2014, 43, e181-e185.	1.9	5
92	Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis. Fundamental and Clinical Pharmacology, 2021, 35, 1090-1099.	1.9	5
93	Response to: â€˜Correspondence on â€˜Interleukin 6 receptor inhibition in primary SjÃ¶gren syndrome: a multicentre double-blind randomised placebo-controlled trialâ€™â€™ by de Wolffet al. Annals of the Rheumatic Diseases, 2023, 82, e149-e149.	0.9	5
94	Primary Sjogrenâ€™s Syndrome: Time for Prospective Cohorts. Current Pharmaceutical Biotechnology, 2012, 13, 2022-2025.	1.6	4
95	Therapeutic Recommendations for the Management of Older Adult Patients with SjÃ¶grenâ€™s Syndrome. Drugs and Aging, 2021, 38, 265-284.	2.7	4
96	CritÃ¨res diagnostiques du syndrome de Gougerot-SjÃ¶gren. Revue Du Rhumatisme Monographies, 2013, 80, 20-25.	0.0	3
97	SP0190â€…2019 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SJÃ¶GRENâ€™S SYNDROME WITH TOPICAL AND SYSTEMIC THERAPIES. , 2019, , .		3
98	SjÃ¶gren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. Clinical and Experimental Rheumatology, 2022, 40, 103-112.	0.8	3
99	Fetuin-A and thyroxin binding globulin predict rituximab response in rheumatoid arthritis patients with insufficient response to anti-TNFÎ±. Clinical Rheumatology, 2020, 39, 2553-2562.	2.2	2
100	Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry. Joint Bone Spine, 2022, 89, 105310.	1.6	2
101	Systemic phenotype related to primary SjÃ¶gren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 85-94.	0.8	2
102	Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5â€‰years. Modern Rheumatology, 2023, 33, 64-72.	1.8	2
103	History and outcome of febrile neutropenia related to non-chemotherapy drugs: A retrospective study of the Strasbourg's agranulocytosis cohort. European Journal of Internal Medicine, 2017, 46, e13-e14.	2.2	1
104	AB0458â€…A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÃ–GRENâ€™S SYNDROME (PSS). , 2019, , .		1
105	Syndrome de SjÃ¶gren primitifÂ: avancÃ©es physiopathologiques, cliniques et thÃ©rapeutiques. Revue Du Rhumatisme (Edition Francaise), 2009, 76, 944-948.	0.0	0
106	Syndrome de SjÃ¶gren primitifÂ: critÃ¨res diagnostiques et de suivi. Revue Du Rhumatisme Monographies, 2010, 77, 108-113.	0.0	0
107	Influence of the age at diagnosis in the disease expression of primary SjÃ¶gren syndrome. Analysis of 12,753 patients from the SjÃ¶gren Big Data Consortium.. Clinical and Experimental Rheumatology, 2021, 39 Suppl 133, 166-174.	0.8	0
108	SjÃ¶gren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0